{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T17:07:34Z","timestamp":1721581654128},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["95097"],"award-info":[{"award-number":["95097"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.antiviral.2015.11.011","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T16:46:32Z","timestamp":1450457192000},"page":"90-98","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa"],"prefix":"10.1016","volume":"127","author":[{"given":"N.","family":"Prabdial-Sing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.","family":"Blackard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Puren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mahomed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Abuelhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.11.011_bib1","article-title":"American Association for the study of liver diseases","author":"AASLD","year":"2015","journal-title":"Recomm. Test. Manag. Treat. Hepat. C"},{"key":"10.1016\/j.antiviral.2015.11.011_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.11.011_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jmv.23823","article-title":"Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy","volume":"86","author":"Alhamlan","year":"2014","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"Alves","year":"2013","journal-title":"J.\u00a0viral Hepat."},{"key":"10.1016\/j.antiviral.2015.11.011_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2893.2007.00946.x","article-title":"Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5","volume":"15","author":"Antaki","year":"2008","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.11.011_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jmv.23837","article-title":"Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma","volume":"86","author":"Araujo","year":"2014","journal-title":"J.\u00a0Med. Virol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.antiviral.2015.11.011_bib7","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/cis361","article-title":"Global burden of hepatitis C: considerations for healthcare providers in the United States","volume":"55","author":"Averhoff","year":"2012","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2015.11.011_bib8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2036.2006.03018.x","article-title":"Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study","volume":"24","author":"Bonny","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2015.11.011_bib9","first-page":"20","article-title":"South African hepatitis C management guidelines","author":"Botha","year":"2010","journal-title":"South Afr. Gastroenterol. Rev."},{"key":"10.1016\/j.antiviral.2015.11.011_bib10","doi-asserted-by":"crossref","first-page":"11353","DOI":"10.1128\/JVI.79.17.11353-11365.2005","article-title":"Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features","volume":"79","author":"Boulant","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib11","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2015.11.011_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.antiviral.2015.11.011_bib13","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/JVI.02446-09","article-title":"Regulation of de novo-initiated RNA synthesis in hepatitis C virus RNA-dependent RNA polymerase by intermolecular interactions","volume":"84","author":"Chinnaswamy","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib14","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1073\/pnas.88.6.2451","article-title":"Genetic organization and diversity of the hepatitis C virus","volume":"88","author":"Choo","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2015.11.011_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/prot.24154","article-title":"Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase","volume":"81","author":"Davis","year":"2013","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2015.11.011_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12072-015-9635-z","article-title":"Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients","volume":"9","author":"Devaki","year":"2015","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2015.11.011_bib18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jmv.22049","article-title":"Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials","volume":"83","author":"D'Heygere","year":"2011","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib19","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/molbev\/mss075","article-title":"Bayesian phylogenetics with BEAUti and the BEAST 1.7","volume":"29","author":"Drummond","year":"2012","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2307\/2408678","article-title":"Confidence limits on phylogenies: an approach using the bootstrap","volume":"39","author":"Felsenstein","year":"1985","journal-title":"Evolution"},{"key":"10.1016\/j.antiviral.2015.11.011_bib21","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1128\/JVI.02583-10","article-title":"Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91","volume":"85","author":"Funaoka","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib22","doi-asserted-by":"crossref","first-page":"e88866","DOI":"10.1371\/journal.pone.0088866","article-title":"HCV core residues critical for infectivity are also involved in core-NS5A complex formation","volume":"9","author":"Gawlik","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2015.11.011_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.meegid.2013.10.022","article-title":"Near full-length genome analysis of HCV genotype 5 strains from South Africa","volume":"21","author":"Gededzha","year":"2014","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.11.011_bib24","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/nar\/gkl240","article-title":"Analysis of hepatitis C virus RNA dimerization and core-RNA interactions","volume":"34","author":"Ivanyi-Nagy","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.11.011_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s12072-011-9267-x","article-title":"Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy","volume":"5","author":"Kadokura","year":"2011","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2015.11.011_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jmv.22249","article-title":"Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island","volume":"84","author":"Karatapanis","year":"2012","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00705-010-0797-7","article-title":"Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis","volume":"155","author":"Khan","year":"2010","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib28","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1128\/JVI.79.11.6814-6826.2005","article-title":"Identification of residues in the hepatitis C virus core protein that are critical for capsid assembly in a cell-free system","volume":"79","author":"Klein","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/382544","article-title":"Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin","volume":"189","author":"Legrand-Abravanel","year":"2004","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.11.011_bib30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.11.011_bib31","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1128\/JVI.00793-07","article-title":"Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus","volume":"81","author":"Murray","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2009.10.001","article-title":"Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development","volume":"52","author":"Nakamoto","year":"2010","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib33","doi-asserted-by":"crossref","first-page":"e86413","DOI":"10.1371\/journal.pone.0086413","article-title":"HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil","volume":"9","author":"Nishiya","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2015.11.011_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001432-200312000-00012","article-title":"The nature of interferon-alpha resistance in hepatitis C virus infection","volume":"16","author":"Pawlotsky","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.11.011_bib35","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/bioinformatics\/bti320","article-title":"Datamonkey: rapid detection of selective pressure on individual sites of codon alignments","volume":"21","author":"Pond","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2015.11.011_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.11.011_bib37","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/v2102169","article-title":"Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B","volume":"2","author":"Powdrill","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2015.11.011_bib38","first-page":"21","article-title":"HCV genotypes and response to therapy in a South African study group","volume":"24","author":"Prabdial-Sing","year":"2009","journal-title":"South Afr. J. Epidemiol. Infect."},{"key":"10.1016\/j.antiviral.2015.11.011_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2172-13-67","article-title":"Sequence-based in silico analysis of well studied hepatitis C virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgrounds","volume":"13","author":"Prabdial-Sing","year":"2012","journal-title":"BMC Immunol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib40","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00705-008-0227-2","article-title":"Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa","volume":"153","author":"Prabdial-Sing","year":"2008","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib41","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1128\/JVI.68.6.3631-3641.1994","article-title":"Biosynthesis and biochemical properties of the hepatitis C virus core protein","volume":"68","author":"Santolini","year":"1994","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib42","first-page":"249","article-title":"Hepatitis C genotype 5a mutations in the core and nonstructural regions (NS5A) and responses to combination therapy","volume":"28","author":"Seleka","year":"2013","journal-title":"South Afr. J. Epidemiol. Infect."},{"key":"10.1016\/j.antiviral.2015.11.011_bib43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1478-3231.2009.02164.x","article-title":"Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C","volume":"30","author":"Tachi","year":"2010","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.antiviral.2015.11.011_bib44","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: molecular evolutionary genetics analysis version 6.0","volume":"30","author":"Tamura","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib45","first-page":"19","article-title":"Human immunodeficiency virus and hepatitis B and C co- infection in Kwa-Zulu Natal: a retrospective analysis of a laboratory database","volume":"29","author":"Tathiah","year":"2014","journal-title":"South Afr. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.11.011_bib46","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1093\/nar\/25.24.4876","article-title":"The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools","volume":"25","author":"Thompson","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.11.011_bib47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27850","article-title":"Value anti-hepatitis C virus therapy by its clinical efficacy","volume":"62","author":"van der Meer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.11.011_bib48","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1128\/JVI.80.9.4220-4226.2006","article-title":"Investigating the origin and spread of hepatitis C virus genotype 5a","volume":"80","author":"Verbeeck","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"Vermehren","year":"2012","journal-title":"Best Practice Res. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2893.2011.01449.x","article-title":"Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b","volume":"19","author":"Vermehren","year":"2012","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.11.011_bib51","doi-asserted-by":"crossref","first-page":"D854","DOI":"10.1093\/nar\/gkp1004","article-title":"The immune epitope database 2.0","volume":"38","author":"Vita","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.11.011_bib52","doi-asserted-by":"crossref","first-page":"e1000048","DOI":"10.1371\/journal.pcbi.1000048","article-title":"A\u00a0systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach","volume":"4","author":"Wang","year":"2008","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.antiviral.2015.11.011_bib53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/1471-2105-11-568","article-title":"Peptide binding predictions for HLA DR, DP and DQ molecules","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.antiviral.2015.11.011_bib55","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1128\/AAC.03534-14","article-title":"Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents","volume":"58","author":"Wose Kinge","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.11.011_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.meegid.2013.08.014","article-title":"A\u00a0panel of 16 full-length HCV genomes was characterized in China belonging to genotypes 1-6 including subtype 2f and two novel genotype 6 variants","volume":"20","author":"Xu","year":"2013","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T23:41:21Z","timestamp":1599954081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215300358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":54,"alternative-id":["S0166354215300358"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.011","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}